Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04948060 · ClinicalTrials.gov registry record · NA

Tribally Engaged Approaches to Lung Screening (TEALS)

A NA study of Lung Cancer, sponsored by University of Oklahoma.

Recruiting
Registry status
NA
Development phase
480
Enrollment target
1
Study location

NCT04948060 is a NA study of Lung Cancer that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 480 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04948060, a NA study of Lung Cancer, is actively recruiting participants, sponsored by University of Oklahoma.

RECRUITING
Registry status
NA
Development phase
480 participants
Enrollment target
1
Study location

Study Summary

Lung cancer is the leading cause of cancer mortality among American Indians and Alaska Natives (AI/AN), and AI/AN have worse lung cancer incidence rates, survival, and death compared to the general population. Because lung cancer screening (LCS) with low-dose computed tomography (LDCT) has been shown to reduce lung cancer mortality by roughly 20%, the United States Preventive Services Task Force now recommends LCS for men and women aged 55-80 years who meet specific eligibility criteria (grade-B evidence), and subsequently the Center for Medicare and Medicaid Services (CMS) opted to cover this test. However, the uptake of LCS implementation has been slow in most healthcare systems, and LCS implementation among AI/AN has never been studied. To address this knowledge, we prose the "Tribally Engaged Approaches to Lung Screening (TEALS)" study, which is a collaborative effort between the Choctaw Nation of Oklahoma, the Stephenson Cancer Center, and the University of Oklahoma Health Sciences Center. Over the course of 5 years, TEALS will: 1. Conduct focus groups and semi-structured interviews with CNHSA patients, clinicians, and health administrators to elucidate individual- and system-level barriers and facilitators that affect the implementation of LCS; 2. Develop an LCS care coordination intervention that will identify eligible persons for LCS, help these patients navigate the screening process, and link them with smoking cessation services, when applicable; 3. Measure the impact of the TEALS intervention on the receipt of screening and a set of patient- and practice-level outcomes by conducting a cluster-randomized clinical trial of LCS implementation; and 4. Disseminate the TEALS program to other researchers and healthcare systems that serve AI/AN patients. TEALS will bridge the gap between evidence and clinical practice for LCS in a high-need, low-resource setting by intervening at the level of the healthcare system. System-level interventions for guideline imp

Conditions Studied

Interventions

  • OTHER Enhanced lung cancer screening services

Study Locations (1)

Oklahoma

  • University of Oklahoma Health Sciences Center - Oklahoma City

Trial Details

FieldValue
Enrollment Target 480 participants
Start Date 2022-01-01
Est. Completion 2025-08-31
Phase NA

Sponsor

University of Oklahoma

358 total trials

What the Registry Record Tells You About NCT04948060

The ClinicalTrials.gov registry entry for NCT04948060 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (49% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Enhanced lung cancer screening services is the first listed.

NCT04948060 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT04948060 about?

NCT04948060 is a clinical study titled "Tribally Engaged Approaches to Lung Screening (TEALS)". Lung cancer is the leading cause of cancer mortality among American Indians and Alaska Natives (AI/AN), and AI/AN have worse lung cancer incidence rates, survival, and death compared to the general population. Because lung cancer screening (LCS) with low-dose computed tomography (LDCT) has been show...

What is the current status of trial NCT04948060?

This trial is currently recruiting. It is a NA study. The enrollment target is 480 participants. The study started on 2022-01-01. Estimated completion is 2025-08-31.

What conditions does trial NCT04948060 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT04948060?

The interventions under investigation include: Enhanced lung cancer screening services (OTHER).

Who is sponsoring clinical trial NCT04948060?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04948060 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.